Penumbra, which is set to become part of Boston Scientific this year, is running the trial to inform the treatment of a type of medium-vessel blockage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results